Boston Scientific stock price target raised to $124 by Wells Fargo on PFA growth

Boston Scientific (BSX) reported strong second-quarter results, with sales of $5.06 billion and EPS of $0.75, both exceeding analyst expectations, primarily driven by its Pulse Field Ablation technology and Watchman device. Following this performance, the company raised its 2025 organic growth guidance to 14-15% and increased its earnings per share guidance to $2.95-$2.99, while also improving its operating margin outlook. In response, Wells Fargo raised its price target to $124 and BofA Securities to $120, affirming positive analyst sentiment despite the stock trading near its 52-week high and some analysis suggesting it appears overvalued.

Analysis

Boston Scientific (BSX) has demonstrated significant operational momentum, reporting second-quarter sales of $5.06 billion, which reflects a 17.4% organic growth rate and surpasses analyst consensus of $4.9 billion. The primary drivers for this outperformance are its Pulse Field Ablation (PFA) technology, which fueled a 117% year-over-year growth in U.S. electrophysiology, and the expanding adoption of its Watchman device. This strong performance prompted management to raise its full-year 2025 guidance, now forecasting 14-15% organic growth and an EPS of $2.95-$2.99, which is above the $2.92 consensus. Furthermore, the company anticipates operating margin expansion of 75-100 basis points, an increase from its prior forecast. The positive results and outlook have been validated by analyst actions, with Wells Fargo raising its price target to $124 and BofA Securities to $120. However, this bullish fundamental picture is juxtaposed with valuation concerns, as the stock trades near its 52-week high with a P/E ratio of 61.4x, and is noted as appearing overvalued by some metrics.

Key Decisions for Investors

• Given the strong earnings beat and upwardly revised guidance, investors may view any price pullbacks as potential buying opportunities, especially if they have a long-term bullish thesis on the medical device sector and the company's PFA technology leadership.
• Investors should weigh the robust growth drivers against the stock's high valuation, as the 61.4x P/E ratio suggests significant growth is already priced in, potentially limiting near-term upside and increasing vulnerability to market shifts.
• It is critical to monitor the continued adoption rates of the Farapulse and Watchman devices and execution in key international markets like China and Japan, as these factors are essential to justify the premium valuation and achieve the new, higher growth targets.